Ulf Jungnelius, MD
Education/Background: Oncology Specialist with a diploma from Karolinska Institute, along with clinical experience from Radiumhemmet in Stockholm. Dr. Jungnelius has extensive experience in international clinical research & development in the field of oncology. He has held executive positions at several international companies such as Eli Lilly, Pfizer, Takeda, and Celgene.
Current Assignments: Henrik is CEO at Isofol Medical AB, a Board member at Oncopeptides AB, and CARPONOVUM AB.
Holdings: 25,000 TO4, 25,000 TO7, 25,000 TO10
Some of our Collaborations
Numbers of patients in studies